Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Genentech, a member of the Roche Group, has dosed for the first time in humans a clinical trial candidate containing a Symplex generated antibody conjugated to an undisclosed active agent.
Chief Executive Officer of Symphogen Kirsten Drejer, PhD stated: “The Genentech collaboration has allowed Symphogen to extend application of our integrated antibody discovery technologies to create value in therapeutic applications outside Symphogen’s oncology focus and we are pleased to see this important compound advance into the clinic’.
For additional information, please contact:
Kirsten Drejer
Chief Executive Officer
Phone: + 45 22 10 99 59
E-mail: kd@symphogen.com
Gayle Mills
Chief Business Officer
Phone: +1 650 464-3656
E-mail: gmm@symphogen.com
Media Inquiries
Heidi K. Roennest
Executive Office Manager
+45 4526 5050
hkr@symphogen.com